This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IDRA Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Idera Pharmaceuticals Stock (NASDAQ:IDRA) 30 days 90 days 365 days Advanced Chart Get Idera Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.17▼$7.2352-Week Range N/AVolume21,870 shsAverage Volume464,030 shsMarket Capitalization$450.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. Read More Receive IDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDRA Stock News HeadlinesEnergy Recovery Wins “Breakthrough Innovation Award†at IDRA World CongressDecember 16, 2024 | businesswire.comEkso Bionics (NASDAQ: EKSO)April 11, 2024 | fool.comIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.September 15 at 2:00 AM | American Alternative (Ad)Kiniksa PharmaceuticalsNovember 15, 2023 | forbes.comNabriva Therapeutics AG (NBRVF)August 9, 2023 | investing.comMarginaliaApril 26, 2023 | npr.orgNA mysterious rift propels the story in ‘Take What You Need’March 17, 2023 | washingtonpost.comIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookJanuary 18, 2023 | finanznachrichten.deSee More Headlines IDRA Stock Analysis - Frequently Asked Questions How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. When did Idera Pharmaceuticals' stock split? Idera Pharmaceuticals's stock split on Friday, November 25th 2022.The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were payable to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX). Company Calendar Last Earnings11/08/2021Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IDRA CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees32Year Founded1989Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$98.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.74% Return on Assets-34.26% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow0.29 Book Value$0.56 per share Price / BookN/AMiscellaneous Outstanding Shares62,355,000Free Float59,206,000Market Cap$450.52 million OptionableOptionable Beta1.25 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:IDRA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Idera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
